NCT06379217 2026-03-11
NEPC Study: An Exploratory Safety and Efficacy Study With PSMA, SSTR2 and GRPR Targeted Radioligand Therapy in Metastatic Neuroendocrine Prostate Cancer.
Novartis
Phase 1 Active not recruiting
Novartis
Australasian Leukaemia and Lymphoma Group
National Institutes of Health Clinical Center (CC)
Spanish Breast Cancer Research Group
Roswell Park Cancer Institute
China Medical University Hospital
Amsterdam UMC, location VUmc
Merck Sharp & Dohme LLC
Medtronic - MITG
All India Institute of Medical Sciences
Sanofi
Radboud University Medical Center
Swiss Cancer Institute
Mahidol University